Recursion Pharmaceuticals, Inc. RXRX Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $665.18M+30.6% | $753.92M+25.0% | $667.15M+53.1% | $533.85M+10.6% | $509.16M+66.3% | ||
| $5.51M+79.2% | $4.59M+50.9% | $3.14M+102% | $3.11M+74.2% | $3.08M-3.8% | ||
| $11.74M+375% | $11.74M-60.3% | $0-100% | $0-100% | $2.47M-94.0% | ||
| —— | —— | —— | —— | —— | ||
| $709.56M+21.5% | $812.85M+13.8% | $714.11M+50.6% | $587.16M+12.4% | $584.15M+70.0% | ||
| $95.81M-24.5% | $103.93M-26.3% | $111.71M+32.3% | $120.04M+43.5% | $126.83M+46.3% | ||
| $87.63M+127% | $75.78M+185% | $63.49M+12.4% | $51.16M-2.5% | $38.57M-21.0% | ||
| $42.82M-19.5% | $45.34M-31.2% | $47.81M+60,521,518,887% | $50.32M+64,517,948,618% | $53.19M+69,072,727,173% | ||
| $160.17M+1.3% | $162.16M+8.9% | $162.04M+211% | $164.27M+216% | $158.11M+204% | ||
| $294.07M-12.4% | $309.9M-7.7% | $322.34M+845% | $341.32M+793% | $335.79M+946% | ||
| $18.28M-18.5% | $23.26M+40.3% | $23.31M+13,776% | $23.78M— | $22.44M+4,149% | ||
| $12.25M-17.1% | $12.75M+44.5% | $14.66M+3,973% | $9.42M+2,957% | $14.78M+5,718% | ||
| $1.34B+2.6% | $1.47B+1.8% | $1.4B+92.6% | $1.3B+67.9% | $1.31B+134% | ||
| $71.72M+36.0% | $76.45M+133% | $79.95M+430% | $68.27M+299% | $52.72M+242% | ||
| $14.57M-35.1% | $31.77M-61.2% | $24.06M+22.3% | $29.7M+126% | $22.46M+123% | ||
| $32.79M-17.3% | $37.61M-39.1% | $47.36M-4.5% | $39.69M+23.2% | $39.65M+8.3% | ||
| $9.27M+7.9% | $9.09M— | $8.92M— | $8.75M— | $8.59M— | ||
| $13.09M+10.4% | $12.66M-8.2% | $11.53M+40.0% | $11.73M+36.3% | $11.85M+95.5% | ||
| $114.72M-11.5% | $114.01M-4.0% | $111.2M+608% | $126.24M+333% | $129.61M+247% | ||
| $129.7M-8.7% | $147.71M-21.2% | $155.1M+42.4% | $164.03M+90.5% | $141.98M+92.1% | ||
| $7.18M-56.3% | $9.56M-49.7% | $11.9M-42.0% | $14.2M-38.1% | $16.45M+1,436% | ||
| $42.84M-23.5% | $46.65M-30.6% | $50.03M-6.8% | $53.4M+6.3% | $56.02M+27.9% | ||
| $16.2M-34.1% | $18.34M— | $20.5M— | $22.6M— | $24.6M— | ||
| $16.2M-34.1% | $9.37M— | $20.5M— | $22.6M— | $24.6M— | ||
| $2.03M-57.7% | $2.08M— | $1.03M— | $1.57M— | $4.79M— | ||
| $314.75M-15.2% | $343.27M-17.0% | $352.58M+74.6% | $383.21M+100% | $371.29M+137% | ||
| 2B0.0% | 2B+49,999,900% | 2B0.0% | 2B0.0% | 2B0.0% | ||
| $3.19B+25.0% | $3.17B+28.2% | $2.98B+67.7% | $2.68B+54.0% | $2.55B+74.9% | ||
| -$2.19B-34.3% | -$2.08B-45.0% | -$1.97B-57.1% | -$1.81B-56.1% | -$1.63B-54.3% | ||
| $26.66M— | $36.72M— | $34.09M— | —— | —— | ||
| $1.02B+9.7% | $1.13B+9.3% | $1.05B+99.6% | $919.15M+57.3% | $933.95M+133% | ||
| $1.34B+2.6% | $1.47B+1.8% | $1.4B+92.6% | $1.3B+67.9% | $1.31B+134% | ||
| $24.25M-24.3% | $28.57M-25.0% | $29.22M-31.6% | $37.34M-14.6% | $32.02M-22.8% | ||
| $13.59M-70.5% | $24.65M-49.9% | $21.91M+872% | $21.61M+755% | $46.12M+1,675% | ||
| $13.59M-70.5% | $24.65M-49.9% | $21.91M+872% | $21.61M+755% | $46.12M+1,675% | ||
| $12.25M-17.1% | $12.75M+44.5% | $14.66M+3,973% | $9.42M+2,957% | $14.78M+5,718% | ||
| $135.55M+2.1% | $138.02M+7.2% | $137.88M+13,884% | $140.65M+14,165% | $132.74M+13,362% | ||
| $135.55M+2.1% | $138.02M+7.2% | $137.88M+13,884% | $140.65M+14,165% | $132.74M+13,362% | ||
| $135.55M+2.1% | $138.02M+7.2% | $137.88M+13,884% | $140.65M+14,165% | $132.74M+13,362% | ||
| $135.55M+2.1% | $138.02M+7.2% | $137.88M+13,884% | $140.65M+14,165% | $132.74M+13,362% | ||
| $381.71M+2.0% | $385.68M+6.4% | $385.83M+609% | $392.48M+621% | $374.36M+724% | ||
| $42.82M-19.5% | $45.34M-31.2% | $47.81M-0.1% | $50.32M+14.1% | $53.19M+49.8% | ||
| $957K— | $957K— | $957K— | —— | —— | ||
| $294.07M-12.4% | $309.9M-7.7% | $322.34M+845% | $341.32M+793% | $335.79M+915% | ||
| $42.82M-19.5% | $45.34M-31.2% | $47.81M-0.1% | $50.32M+14.1% | $53.19M+49.8% | ||
| $12.25M-17.1% | $12.75M+44.5% | $14.66M+3,973% | $9.42M+2,957% | $14.78M+5,718% | ||
| $42.82M-19.5% | $45.34M-31.2% | $47.81M-0.1% | $50.32M+14.1% | $53.19M+49.8% | ||
| $12.25M-17.1% | $12.75M+44.5% | $14.66M+3,973% | $9.42M+2,957% | $14.78M+5,718% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $14.57M-35.1% | $31.77M-37.5% | $24.06M+22.3% | $29.7M+126% | $22.46M+123% | ||
| $114.72M-11.5% | $114.01M-4.0% | $111.2M+608% | $126.24M+333% | $129.61M+247% | ||
| $54.21M-4.6% | $70.23M-14.2% | $53.1M+30.8% | $64.28M+92.4% | $56.8M+118% | ||
| $54.21M-4.6% | $70.23M-14.2% | $53.1M+30.8% | $64.28M+92.4% | $56.8M+118% | ||
| $14.57M-35.1% | $31.77M-37.5% | $24.06M+22.3% | $29.7M+126% | $22.46M+123% | ||
| $9.27M+7.9% | $9.09M— | $8.92M— | $8.75M— | $8.59M— | ||
| $1.88M— | $1.23M— | $1.96M— | $2.22M— | —— | ||
| $114.72M-11.5% | $114.01M-4.0% | $111.2M+608% | $126.24M+333% | $129.61M+247% | ||
| $7.18M-56.3% | $9.56M— | $11.9M— | $14.2M— | $16.45M— | ||
| $114.72M-11.5% | $114.01M-4.0% | $111.2M+608% | $126.24M+333% | $129.61M+247% | ||
| $88.58M-24.6% | $96.3M-28.7% | $102.87M-13.0% | $110.68M-7.6% | $117.51M+131% | ||
| $0.000.0% | $0.000.0% | $0.000.0% | $0.000.0% | $0.000.0% | ||
| 530.6M+30.6% | 528.2M+33.1% | 491.8M+71.9% | 432.8M+54.0% | 406.4M+71.1% | ||
| $5K+25.0% | $5K+25.0% | $5K+66.7% | $4K+33.3% | $4K+100% | ||
| —— | —— | —— | —— | —— | ||
| $4.21M-45.1% | $2.69M-53.7% | $2.5M-27.7% | $6.87M+76.2% | $7.67M+32.1% | ||
| $7.54M+29.3% | $4.58M+48.0% | $7.84M+166% | $10.18M+173% | $5.83M+123% | ||
| $4.92M— | $3M— | $3M— | —— | —— | ||
| $1.88M— | $1.23M— | $1.96M— | $2.22M— | —— | ||
| $00.0% | $00.0% | $00.0% | $00.0% | $00.0% | ||
| $2B0.0% | $2B0.0% | $2B0.0% | $2B0.0% | $2B0.0% | ||
| $530.63M+30.6% | $528.18M+33.1% | $491.8M+71.9% | $432.83M+54.0% | $406.41M+71.1% | ||
| $530.63M+30.6% | $528.18M+33.1% | $491.8M+71.9% | $432.83M+54.0% | $406.41M+71.1% | ||
| $18.28M-18.5% | $23.26M+40.3% | $23.31M+13,776% | $23.78M— | $22.44M+4,149% | ||
| $18.69M-24.5% | $20.21M— | $21.73M— | $23.24M— | $24.76M— | ||
| —— | —— | —— | —— | —— | ||
| $87.63M+127% | $75.78M+185% | $63.49M+212% | $51.16M+216% | $38.57M+213% | ||
| $135.55M+2.1% | $138.02M+7.2% | $137.88M+13,884% | $140.65M+14,165% | $132.74M+13,362% | ||
| $381.71M+2.0% | $385.68M+6.4% | $385.83M+609% | $392.48M+621% | $374.36M+724% | ||
| $7.18M-56.3% | $9.56M— | $11.9M— | $14.2M— | $16.45M— | ||
| $9.27M+7.9% | $9.09M— | $8.92M— | $8.75M— | $8.59M— | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $1.01M-38.0% | $703K-55.8% | $1.21M-36.2% | $1.54M-19.9% | $1.63M+37.5% | ||
| —— | —— | —— | —— | —— | ||
| $12.56M+12.0% | $17.97M+7.4% | $12.55M+57.6% | $10.77M+39.3% | $11.21M+74.6% | ||
| $11.74M— | $11.74M— | $0— | —— | —— | ||
| —— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Recursion Pharmaceuticals, Inc.'s total assets?
- Recursion Pharmaceuticals, Inc. (RXRX) holds $1.3B in total assets, up 2.6% year over year.
- How much debt does Recursion Pharmaceuticals, Inc. have?
- Recursion Pharmaceuticals, Inc. carries $88.6M in total debt against $1.0B of shareholders' equity, a debt-to-equity ratio of 0.09.
- How much cash does Recursion Pharmaceuticals, Inc. have?
- Recursion Pharmaceuticals, Inc. holds $665.2M in cash and equivalents.
- Can Recursion Pharmaceuticals, Inc. cover its short-term obligations?
- Its current ratio is 5.47 — current assets exceed current liabilities.
- Where does Recursion Pharmaceuticals, Inc.'s balance sheet data come from?
- Every line is extracted from Recursion Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
